Cancer Epidemiology最新文献

{"title":"Patient demographic and prognostic factors of vulvar squamous cell carcinoma: A National Cancer Database Study","authors":"Grace Folino ,&nbsp;Elizabeth Byrne ,&nbsp;Mya Hendry ,&nbsp;Peter Silberstein ,&nbsp;Marco DiBlasi","doi":"10.1016/j.canep.2025.102933","DOIUrl":"10.1016/j.canep.2025.102933","url":null,"abstract":"<div><h3>Background</h3><div>Vulvar Squamous Cell Carcinoma (VSCC) incidence rates and clinical outcomes are correlated with demographic factors, but no study expansively investigates demographic and prognostic factors of VSCC in relation to survival in the post-Gardasil era. This study aims to investigate underlying disparities in VSCC and correlate these factors with survival.</div></div><div><h3>Methods</h3><div>Patients were identified from the National Cancer Database using ICD-10 codes specific for vulvar structures, ICD-O-3 histology codes for squamous cell carcinoma and pre-malignant vulvar intraepithelial neoplasia Grade III (VIN3), and patient data from 2007 to 2021. Statistical analyses utilized IBM SPSS and GraphPad Prism to determine variable frequency with cross analysis and Chi-Squared tests, Kaplan Meier Survival Curves with Log-Rank Pairwise Comparison, and Cox Proportional Hazards Regression Models.</div></div><div><h3>Results</h3><div>The total patient population was 58,732 patients after inclusion criteria. The median age of diagnosis was 64.0 years old. Significant prognostic factors resulting in better survival included VIN3 histology, lower Charlson-Deyo Score, Black race, receiving care from Academic/Research Programs, private insurance, and median income greater than $63,000. Surgical procedures were significant in improving survival. Black patients are diagnosed younger than White and Other races. A histology type of VIN3 was associated with increased survival time, indicating early identification and treatment for better outcomes.</div></div><div><h3>Conclusion</h3><div>Key demographic and prognostic factors that influence survival were identified across the VSCC population. This study may serve as a tool in reevaluation of current gynecological screening protocols to promote early diagnosis and management for the entire VSCC patient population.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102933"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer incidence and mortality in Italy, 2013–2017","authors":"Andrea Tittarelli ,&nbsp;Sabrina Fabiano ,&nbsp;Viviana Perotti ,&nbsp;Maurizio Zarcone ,&nbsp;Maria Teresa Pesce ,&nbsp;Alessio Gili ,&nbsp;Fabrizio Stracci ,&nbsp;Walter Mazzucco ,&nbsp;Luigino Dal Maso ,&nbsp;Emanuele Crocetti ,&nbsp;Riccardo Capocaccia ,&nbsp;Giovanna Tagliabue ,&nbsp;Paolo Contiero ,&nbsp;AIRTUM Working Group","doi":"10.1016/j.canep.2025.102905","DOIUrl":"10.1016/j.canep.2025.102905","url":null,"abstract":"<div><div>The demographic transition, together with changes in lifestyles and the exposure to other risk factors, contributed to a rising burden of chronic degenerative diseases, including cancer, in Italy. We provided updated figures on cancer incidence and mortality in Italy during the period 2013–2017, using data provided by 34 population-based cancer registries from the AIRTUM network. Age-standardized incidence rates (ASRs) and age-standardized mortality rates (ASMRs) per 100,000 were estimated, stratified by sex, cancer site or type, and macroarea. The cumulative risk (number of individuals who need to be followed over a lifetime for one to develop cancer), stratified by cancer site and sex, was estimated. Overall, 1,359,053 incident cancer cases (52.8 % in men) were registered during the surveillance period. The ASR for all malignant tumours was 657.1 per 100,000 among men and 475.5 per 100,000 among women. We documented the highest ASRs for all cancer sites in both sexes (males: 685.7 per 100,000, females: 496.1 per 100,000) in the North, followed by the Center (males: 646.6 per 100,000, females: 488.1 per 100,000), and the South and Islands (males: 626.7 per 100,000, females: 435.4 per 100,000). Mortality rates are less than half that of incidence rates (SMR was 331.8 per 100,000 men and 188.8 per 100,000 women), with negligible differences among Italian areas. One man out of two and 1 women out of three may develop a cancer in their lifetime. Despite incidence and mortality figures in Italy were almost aligned with the ones documented in Europe, our findings recalled the importance for policy-makers to implement national policies and community-based prevention strategies aimed at reducing the cancer burden.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102905"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Half a century of cancer transition in Hungary: A visualization and assessment of mortality dynamics in the Lexis diagram, 1970–2020","authors":"András Wéber ,&nbsp;Freddie Bray ,&nbsp;Mátyás Árvai ,&nbsp;Lászlóné Hilbert ,&nbsp;Dávid Kelemen ,&nbsp;Péter Nagy ,&nbsp;István Kenessey ,&nbsp;Csaba Polgár","doi":"10.1016/j.canep.2025.102925","DOIUrl":"10.1016/j.canep.2025.102925","url":null,"abstract":"<div><h3>Objectives</h3><div>Hungary is among the countries with the highest cancer mortality burden in Europe, consequently there is a crucial need to monitor changes in death rates in the population using appropriate surveillance tools. The Lexis diagram provides a means to depict age, period and cohort influences on long-term cancer mortality trends.</div></div><div><h3>Methods</h3><div>Age-specific mortality rates for six cancer localizations were constructed based on the Deaths Register of the Hungarian Central Statistical Office and the Human Mortality Database, then smoothed (p-splines) within the cells of the Lexis diagram assuming Poisson distribution. After calculating the annual percentage change in mortality rates, the results were visualized using heat maps.</div></div><div><h3>Results</h3><div>Substantial reduction in mortality was observable from the mid-1990s in both sexes as a strong period effect, depicting two distinct epidemiological eras in Hungary. Since 2010, breast cancer mortality in women among ages 70–90 (those born between 1930 and 1950) has been rising. Women born between 1940 and 50 experienced two plateaus in lung cancer mortality, unlike men, emphasizing the delayed nature of the smoking epidemic.</div></div><div><h3>Conclusions</h3><div>The results align with cancer transition patterns observed in similarly developed countries and emphasize a critical need to expand the implementation of effective primary and secondary prevention measures. This includes sustaining organized screening and anti-smoking programs, as well as introducing lung cancer screening with low-dose CT.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102925"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional intake of ω-3 fatty acid intake and clinical grade of prostate cancer","authors":"Nagi B. Kumar ,&nbsp;Saira Bahl ,&nbsp;Daniel Lemay ,&nbsp;Jasreman Dhillon ,&nbsp;Michael Poch ,&nbsp;Brandon Manley ,&nbsp;Roger Li ,&nbsp;Julio Pow-Sang ,&nbsp;Alice Yu ,&nbsp;Junmin Whiting ,&nbsp;Michael J. Schell","doi":"10.1016/j.canep.2025.102959","DOIUrl":"10.1016/j.canep.2025.102959","url":null,"abstract":"<div><h3>Background</h3><div>Recent laboratory and some human studies have shown that ω-3 fatty acids (FA) can inhibit tumor cell growth and induce a local anti-tumor inflammatory response, independently of androgen levels in prostate cancer (PCa) models. Our objective was to conduct a cohort study to evaluate if PCa patients with higher intake of ω-3 FA intake prior to diagnosis will have lower grade prostate tumors as determined by Gleason score at diagnosis compared to those men who consume relative lower quantities of ω-3 FA.</div></div><div><h3>Methods</h3><div>We recruited 172 newly diagnosed men with PCa at the Moffitt Cancer Center, who completed a validated epidemiological, food frequency questionnaire specifically to measure ω-3 fatty acid intake and consented to provide their medical information.</div></div><div><h3>Results</h3><div>Our results indicated that ω-3 FA intake had no impact on grade at diagnosis of PCa. In the multivariate model, ω-3 FA intake indicated a trend toward higher intake being associated with low Gleason grade after adjusting for age and PSA (P &lt; o.25). A novel observation in this study is that, overall, ω-3 fatty acid intake of all men diagnosed with PCa (mean: 2.8 g /week) in this cohort was significantly lower (75 % lower) than the recommendations of the USRDA for optimal ω-3 fatty acid (11.2 g per week).</div></div><div><h3>Conclusion</h3><div>With our understanding of the benefits of ω-3 fatty acid intake for overall health, including its role in preventing prostate carcinogenesis, the overall significantly low dietary intake of ω-3 fatty acid in this cohort may be concerning, requiring further education. Additionally, the role of dietary ω-3 fatty acid intake in the modulation of biomarkers of PCa in general, warrants further studies.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102959"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between sociodemographic and clinical factors and utilization of hematopoietic cell transplant in acute myeloid leukemia from 2004 to 2020","authors":"Utsav Joshi ,&nbsp;Aditya Ravindra ,&nbsp;Bradley Loeffler ,&nbsp;Uttam Bhetuwal ,&nbsp;Shishir Acharya ,&nbsp;Chengu Niu ,&nbsp;Avantika Pyakuryal ,&nbsp;Vijaya Raj Bhatt ,&nbsp;Prajwal Dhakal","doi":"10.1016/j.canep.2025.102952","DOIUrl":"10.1016/j.canep.2025.102952","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigates the influence of sociodemographic and clinical factors on the utilization of hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) between 2004 and 2020.</div></div><div><h3>Methods</h3><div>Patients identified from the National Cancer Database were grouped into two cohorts (2004–2010 and 2011–2019) to assess HCT trends. An additional analysis was conducted for 2020 to characterize HCT use after the onset of the COVID-19 pandemic. Logistic regression and multivariable analysis were used to estimate the influence of patient characteristics on the odds of receiving HCT.</div></div><div><h3>Results</h3><div>Among 67,895 AML patients, 6968 (10.3 %) underwent HCT, with usage rising from 7.2 % in 2004–13.4 % in 2019. There was a notable increase in HCT utilization among patients &gt; 70 years (0.4 % in 2004–2010–2.5 % in 2011–2019), Black patients (4.6–7.7 %), those with public insurance (3.2–6.2 %), and individuals with higher Charlson Comorbidity Index (CCI 1: 5.3–8.2 %; CCI 2–3: 1.9–4.8 %). Younger patients exhibited a higher likelihood of receiving HCT, with usage declining significantly with age and increasing CCI. Key factors such as race, education, income, insurance status, and AML subtype were significantly associated with HCT utilization (p &lt; 0.01). Remarkably, HCT utilization for AML remained stable at 13.1 % in 2020 amid COVID-19 pandemic, comparable to 2019.</div></div><div><h3>Conclusion</h3><div>The rate of HCT utilization has continued to increase over time, with notable positive trends across various demographic groups. Despite this, substantial barriers related to sociodemographic and clinical factors hinder equitable treatment access, highlighting urgent need to address these inequities to enhance patient outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102952"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational heat exposure and stomach cancer risk in a pooled analysis of two Spanish case-control studies in the stomach cancer pooling project – StoP consortium","authors":"Alice Hinchliffe ,&nbsp;Miquel Vallbona-Vistós ,&nbsp;Juan Alguacil ,&nbsp;Manolis Kogevinas ,&nbsp;Sanni Uuksulainen ,&nbsp;Nuria Aragonés ,&nbsp;Adonina Tardón ,&nbsp;Jesus Vioque ,&nbsp;Mary H. Ward ,&nbsp;Charles S. Rabkin ,&nbsp;M. Constanza Camargo ,&nbsp;Claudio Pelucchi ,&nbsp;Carlo La Vecchia ,&nbsp;Paolo Boffetta ,&nbsp;Michelle C. Turner","doi":"10.1016/j.canep.2025.102938","DOIUrl":"10.1016/j.canep.2025.102938","url":null,"abstract":"<div><h3>Background</h3><div>Occupational heat stress occurs frequently and is increasing with climate change. Studies of occupational heat exposure and stomach cancer risk are limited. We used data from the international Stomach cancer Pooling (StoP) Project to investigate the relationship between occupational heat exposure and stomach cancer risk in a pooled analysis of two Spanish case-control studies, including 566 stomach cancer cases and 2984 controls.</div></div><div><h3>Methods</h3><div>The Spanish job-exposure matrix, MatEmEsp, was used to assign heat exposure estimates to participant occupations. We evaluated three exposure indices: ever vs. never exposed, cumulative exposure and duration (years). We calculated odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) using unconditional logistic regression models including terms for potential confounders.</div></div><div><h3>Results</h3><div>Overall, 60.6 % of cases and 42.7 % of controls were ever occupationally exposed to heat. Occupational heat exposure was associated with a moderately elevated risk of stomach cancer (OR 1.31; 95 % CI 1.05, 1.63) when comparing ever vs. never exposed individuals in both studies combined. Elevated ORs were also observed across categories of cumulative exposure and duration (p-trend = 0.01 and 0.03, respectively). Findings were robust to additional covariate adjustment and in analysis of never smokers. There was no clear evidence for interaction according to exposure status to other suspected occupational stomach carcinogens.</div></div><div><h3>Conclusion</h3><div>Findings from this study provide some evidence for a positive association between occupational heat exposure and stomach cancer risk. Further research is needed to advance occupational heat assessment tools for epidemiological research as well as studies in more geographically diverse populations.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102938"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining Mendelian randomization and network toxicology to decipher the causal role and molecular mechanisms of environmental pollutants in breast cancer: A focus on Methyl-4-hydroxybenzoate","authors":"Yunchang Yang,&nbsp;Yaofeng Wang,&nbsp;Yunqin Sun","doi":"10.1016/j.canep.2025.102953","DOIUrl":"10.1016/j.canep.2025.102953","url":null,"abstract":"<div><h3>Background</h3><div>Methylparaben (MEP), a ubiquitous preservative, is an endocrine disruptor with established estrogenic activity. However, its potential non-estrogenic mechanisms and causal role in breast cancer (BC) remain inadequately explored.</div></div><div><h3>Methods</h3><div>We employed an integrative multi-omics approach. A two-sample Mendelian randomization (MR) analysis was conducted using genetic instruments for urinary MEP sulfate (n = 8285) and BC risk data from the FinnGen consortium (n = 182,927). To hypothesize underlying molecular mechanisms, we integrated network toxicology with transcriptomic profiling (TCGA), single-cell/spatial RNA-sequencing, and molecular docking. Shared genes were identified via Venn analysis, followed by protein-protein interaction (PPI) network construction, hub gene identification, and functional enrichment analysis.</div></div><div><h3>Results</h3><div>MR analysis provided evidence consistent with a causal relationship, suggesting that genetically predicted MEP levels are associated with an increased risk of breast cancer (IVW OR = 1.08, 95 % CI: 1.009–1.160, P = 0.027). Network toxicology identified 22 overlapping hub genes connecting MEP targets to BC pathogenesis. Enrichment analyses implicated key oncogenic pathways, including PI3K-Akt and MAPK signaling, as well as metabolic reprogramming. Single-cell and spatial transcriptomics localized predominant expression of hub genes like MYC and ERBB2 within malignant epithelial cells. Molecular docking further suggested plausible, high-affinity binding (binding energy &lt; 0 kcal/mol) of MEP to core targets such as EGFR and JUN.</div></div><div><h3>Conclusion</h3><div>This study provides genetic evidence supporting a potential causal role of MEP in breast cancer. We propose a novel, estrogen receptor-independent mechanistic hypothesis wherein MEP may promote tumorigenesis by dysregulating growth factor signaling, activating key transcription factors, and inducing metabolic reprogramming. These findings highlight the need for a re-evaluation of MEP's public health impact and offer a framework for future experimental validation.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102953"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145440011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatiotemporal patterns in malignant brain and central nervous system cancer incidence and mortality in the United States","authors":"Grace Christensen ,&nbsp;Evan L. Thacker,&nbsp;Chantel Sloan-Aagard","doi":"10.1016/j.canep.2025.102950","DOIUrl":"10.1016/j.canep.2025.102950","url":null,"abstract":"<div><h3>Introduction</h3><div>Brain and nervous system cancers are the 5th most common cancer category in the United States and have a very low survival rate. Spatial analysis techniques can be employed to understand the distribution of rates and generate hypotheses about etiologies. The purpose of this study is to identify geographic patterns, time trends, and sex differences in mortality-incidence rate ratios, incidence rates, and mortality rates of brain and nervous system cancers.</div></div><div><h3>Methods</h3><div>Cancer data were sourced from the CDC Wonder Cancer database, including age-adjusted mortality-incidence rate ratios, age-adjusted incidence and mortality rates for all age groups and demographics in the United States. MIRR data were available from 1999 to 2018 which were split into four, five-year aggregated time windows to have adequate case numbers for time trend analyses. We further conducted joinpoint regression analysis for 1999–2022 (incidence) and 1999–2023 (mortality) by state and sex to identify changes in trends over time.</div></div><div><h3>Results</h3><div>Incidence-mortality rate ratios varied across the United States, with the highest ratios from 1999 to 2003, calculated to be around 0.67 for the different demographics studied. Since 2004, the mortality rates have remained consistent with some variation between states, with little improvement in the incidence-mortality rate ratio. From 2014 to 2018, females had significantly lower incidence and mortality rates compared to men. The average mortality rate for females was 3.7 per 100,000 compared to the mortality rate for males which was 5.5 per 100,000. Average incidence showed the same pattern with a rate of 5.6 per 100,000 in females compared to 7.7 per 100,000 in males. The Northeast region of the United States showed the highest incidence and lowest mortality. There were 12 states that saw a directional change in incidence, and 14 a directional change in mortality during the study window. Females were more likely to have a directional change in mortality, and males a directional change in incidence trends.</div></div><div><h3>Conclusion</h3><div>Further research should investigate reasons for the sex and state differences in brain cancer incidence and mortality rates and how regional factors contribute to survival.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102950"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival disparities in non-small cell lung cancer: Disaggregating Asians from NHPI and identifying variability among common Asian subgroups – The largest single-center study in Hawaiʻi","authors":"Chalothorn Wannaphut ,&nbsp;Manasawee Tanariyakul ,&nbsp;Gene T. Yoshikawa ,&nbsp;Brenda Y. Hernandez ,&nbsp;Nicolas A. Villanueva ,&nbsp;Jared D. Acoba","doi":"10.1016/j.canep.2025.102904","DOIUrl":"10.1016/j.canep.2025.102904","url":null,"abstract":"<div><h3>Background</h3><div>The American Cancer Society and the National Cancer Institute emphasize the need to disaggregate data for U.S. Asian, Native Hawaiian, and Other Pacific Islander (NHPI) populations to better understand racial disparities in cancer outcomes. Asian populations are diverse, with distinct genetic, cultural, and socioeconomic backgrounds that differ from those of NHPI, influencing cancer prognosis. This study analyzes non-small cell lung cancer outcomes among Asian and NHPI populations.</div></div><div><h3>Methods</h3><div>This retrospective cohort study identified NSCLC patients treated at Queen's Medical Center in Honolulu, Hawaiʻi, from 2000 to 2022. Patients were categorized into six racial/ethnic groups: White, Chinese, Japanese, Filipino, Other Asians, and NHPI. Survival differences were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.</div></div><div><h3>Results</h3><div>The cohort comprised 4160 patients, including 977 White, 419 Chinese, 968 Japanese, 724 Filipino, 217 Other Asians, and 855 NHPI patients. NHPI had the highest proportion of individuals under 60 years old (27.5 %), the highest percentage of Medicaid/uninsured (37 %), and the lowest proportion receiving surgery (23.4 %) compared to other races (p &lt; 0.001). Median overall survival (OS) was 20.9 (18.3–23.5) months for White patients, 22.3 (17.8–26.9) months for Chinese patients, 17.7(15.3–20.2) months for Japanese patients, 19.7(16.1–23.3) months for Filipino patients, 25.7(14.7–36.6) months for Other Asians patients and 14.7(12.0–17.3) months for NHPI patients (p &lt; 0.001). Asian NSCLC patients had a lower risk of death compared to White patients (adjusted HR 0.89, 95 % CI 0.85–0.97, p = 0.010). In contrast, NHPI patients had a higher mortality rate compared to White patients (adjusted HR 1.15, 95 % CI 1.03–1.28, p = 0.011) in the multivariable analysis without treatment. However, both associations were no longer statistically significant after additional adjustment for treatment. Subgroup analyses of Asian patients compared to Whites patients revealed that the Chinese patients had the lowest risk of death, with this difference remaining significant even after adjusting for treatment (adjusted HR 0.82, 95 % CI 0.72–0.93, p = 0.003).</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate the heterogeneity in NSCLC outcomes between U.S. Asians and NHPI patients as well as among individual Asian ethnic populations. Further research is needed to validate these differences and their clinical implications.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102904"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do breast cancer survivors benefit from mammography screening? A population-based study","authors":"Bayan Sardini ,&nbsp;Mette Bach Larsen ,&nbsp;Sisse Helle Njor","doi":"10.1016/j.canep.2025.102910","DOIUrl":"10.1016/j.canep.2025.102910","url":null,"abstract":"<div><h3>Background</h3><div>Mammography screening reduces breast cancer mortality by approximately 25 % in the general population and might therefore also benefit breast cancer survivors. However, its impact on mortality rates in this group remains unstudied. We aimed to estimate the effect of mammography screening on breast cancer mortality in this population.</div></div><div><h3>Methods</h3><div>We used data from invitations to the regional mammography screening program in Funen, Denmark (1993–2007), before the nationwide program's rollout in 2008. Breast cancer mortality among invited survivors (study group) was compared to survivors of similar age in counties without screening programs (control group).</div></div><div><h3>Results</h3><div>The study and control groups comprised 2109 invited breast cancer survivors and 15,417 non-invited breast cancer survivors. Of those, 406 (19 %) and 3385 (22 %) died from breast cancer within the follow-up period. The relative risk for invited versus not invited at 22 years of follow-up was 0.88 (95 %CI: 0.81–0.97). The relative risk for participants compared to a similar group in the control group of non-invited breast cancer survivors was 0.62 (95 %CI: 0.51–0.76).</div></div><div><h3>Conclusions</h3><div>Mammography screening might reduce breast cancer mortality less among breast cancer survivors than among the general population. However, this is most likely due to a lower participation rate among breast cancer survivors.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"99 ","pages":"Article 102910"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}